XENETIC BIOSCIENCES, INC. Accounts Payable and Other Accrued Liabilities, Current
XENETIC BIOSCIENCES, INC. (XBIO) had Accounts Payable and Other Accrued Liabilities, Current of $572.44 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $572.44K.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $399.43K.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $709.92K.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $533.52K.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $572.44K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $399.43K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $709.92K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $533.52K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $556.60K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $427.63K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $610.65K 10-K · filed 2026-03-12 |
| 2024-09-30 | $766.06K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.30M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $506.01K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $568.75K 10-K · filed 2025-03-18 |
| 2023-09-30 | $619.94K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $650.03K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $597.18K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $785.80K 10-K · filed 2024-03-21 |
| 2022-09-30 | $848.08K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $806.48K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $782.59K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.06M 10-K · filed 2023-03-22 |
| 2020-12-31 | $609.53K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |